Technology Bundle ID
TAB-3469

Combination Therapy of Human Recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and Chaperones for the Treatment of Mucopolysaccharidosis Type IVA

Applications
Linked ID
E-229-2020-0
Lead Inventors
Wei Zheng (NCATS)
ICs
This technology includes the identification and use of a combination therapy consisting of human recombinant N-acetylgalactosamine-6-sulfate sulfatase (hrGALNS) and the pharmacological chaperone compounds Ezetimibe and Pranlukast for the treatment of Mucopolysaccharidosis Type IVA (MPS IVA). MPS IVA is a rare disease caused by mutations in the gene encoding the lysosomal enzyme N-acetylgalactosamine-6-sulfate sulfatase (GALNS). Currently, hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are available for patients with MPS IVA. This technology includes the combinatorial use of hrGALNS and pharmacological chaperon compounds Ezetimibe and Pranlukast that have been found to have an additive/synergistic effect in reducing enlarged lysosomes in MPS IVA patient cells.
Commercial Applications
Further clinical work with the combination of hrGALNS and chaperones Ezetimibe and Pranlukast could establish these compounds as a treatment for Mucopolysaccharidosis Type IVA.
Competitive Advantages
The pharmacological chaperone compounds Ezetimibe and Pranlukast increase the activity of hrGALNS by a directly binding to it and stabilizing the protein structure. Therefore, these chaperone compounds can reduce the dose of hrGALNS needed for ERT when the two are used in a combination therapy.

Request More Info

Licensing Contact: